Results 11 to 20 of about 910,008 (206)

Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers [PDF]

European Thyroid Journal
Context: Two-thirds of metastatic differentiated thyroid cancer (DTC) patients have radioiodine (RAI)-resistant disease, resulting in poor prognosis and high mortality.
Abdul Rehman Syed, Aakash Gorana, Erik Nohr, Xiaoli-Kat Yuan, Parthiv Amin MASc, Sana Ghaznavi, Debbie Lamb, John McIntyre, Markus Eszlinger, Ralf Paschke   +9 more
doaj   +3 more sources

Repotrectinib in a Patient With <i>NTRK</i> Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome. [PDF]

JCO Precis Oncol
Repotrectinib in a patient with NTRK fusion-positive pancreatic carcinoma and congenital long QT ...
Yun KM, Yun KM, Narezkina A, Redfern C, Velasco K, Bazhenova L.   +5 more
europepmc   +4 more sources

NTRK fusion-positive cancers and TRK inhibitor therapy [PDF]

Nature Reviews Clinical Oncology, 2018
NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types. These fusions can be detected in the clinic using a variety of methods, including tumour DNA and RNA sequencing and plasma cell-free DNA profiling.
E. Cocco, M. Scaltriti, A. Drilon
semanticscholar   +3 more sources

Identifying patients with NTRK fusion cancer [PDF]

Annals of Oncology, 2019
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK ...
James P. Solomon, R. Benayed, J. Hechtman, M. Ladanyi   +3 more
semanticscholar   +4 more sources

<i>NTRK</i> Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy. [PDF]

JCO Precis Oncol
PURPOSE Neurotrophic tropomyosin receptor kinase (NTRK) fusions may act as an oncogenic driver in thyroid carcinomas. Given their low frequency, clinical, pathological, and molecular data on these patients and their responses to targeted therapies are ...
Marczyk VR, Fazeli S, Dadu R, Busaidy NL, Iyer P, Hu MI, Sherman SI, Hamidi S, Hosseini SM, Williams MD, Ahmed S, Routbort MJ, Luthra R, Roy-Chowdhuri S, San Lucas FA, Patel KP, Hong DS, Zafereo M, Wang JR, Maniakas A, Waguespack SG, Cabanillas ME.   +21 more
europepmc   +4 more sources

Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.

PLoS ONE, 2022
The clinical profiles and outcomes of patients with neurotrophic tropomyosin receptor kinase fusion-positive (NTRK+) solid tumors receiving standard of care other than tropomyosin receptor kinase inhibitor (TRKi) targeted therapy have not been well ...
Derrek P Hibar, George D Demetri, Solange Peters, Jessica Davies, Olivier Humblet, Sophia L Maund, Laura Perez   +6 more
doaj   +2 more sources

Interlaboratory Comparison Study (Ring Test) of Next-Generation Sequencing-Based NTRK Fusion Detection in South Korea. [PDF]

Cancer Res Treat, 2023
Purpose: Tropomyosin receptor kinase (TRK) inhibitors are approved for the treatment of neurotrophic receptor tyrosine kinase (NTRK) fusion-positive tumors. The detection of NTRK fusion using a validated method is required before therapeutic application.
Lee SE, Lee MS, Jeon YK, Shim HS, Kang J, Kim J, Choi YL.   +6 more
europepmc   +3 more sources

Clinical characteristics and treatment patterns of patients with NTRK fusion-positive solid tumors: A multisite cohort study at US academic cancer centers. [PDF]

J Manag Care Spec Pharm
BACKGROUND: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare oncogenic drivers prevalent in 0.3% of solid tumors. They are most common in salivary gland cancer (2.6%), thyroid cancer (1.6%), and soft-tissue sarcoma (1.5%).
Willis C, Au T, Hejazi A, Griswold C, Schabath MB, Thompson J, Malhotra J, Federman N, Ko G, Appukkuttan S, Warnock N, Kong SX, Hocum B, Brixner D, Stenehjem D.   +14 more
europepmc   +3 more sources

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. [PDF]

Clin Cancer Res, 2022
Purpose: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable [median duration of response (DoR) 10.4 months] responses in adults with NTRK fusion ...
Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C.   +22 more
europepmc   +2 more sources

Impact of Long-Term Structured Exercise on Body Composition in an NTRK Fusion-Positive NSCLC Patient Treated With Entrectinib. [PDF]

Thorac Cancer
Entrectinib, a first‐generation TRK inhibitor, is effective in NTRK fusion‐positive non‐small cell lung cancer (NSCLC) but commonly induces significant weight gain.
Avancini A, Sposito M, Adamoli G, Borsati A, Ciurnelli C, Scaglione IM, Eccher S, Toniolo L, Tregnago D, Longo L, Insolda J, Milella M, Schena F, Pilotto S, Belluomini L.   +14 more
europepmc   +2 more sources